JBM  Vol.5 No.4 , April 2017
The Effects of All-Trans Retinoic Acid on Vasculogenic Mimicry Formation Ability in CD133+ Glioma Stem Cells and Its Mechanisms
Abstract: Objective: to investigate the effects of all-trans retinoic acid (ATRA) on vasculogenic mimicry formation in glioma stem cells. Methods: U87 stem cells were harvested through a suspension culture assay from the U87 cells, identified by CD133 and nestin, and counted by a flow cytometry. To investigate the VM formation ability of U87 stem cells with the treatment of various concentrations of ATRA, a Matrigel-based tube formation assay was used in the present study in vitro and tube-like structure (typical tube, TT; atypical tube AT) was observed and counted. Then the expressions of VEGF, VEGFR-2 and CD133 were measured throughout real time q-PCR, western blotting and immunofluorescence techniques. The data, presented as the mean ± standard deviation, were analyzed using SPSS software. One-way analysis of variance was used to compare groups and Fisher’s least significant difference tests were performed for subsequent comparisons between groups. P < 0.01 was considered to indicate a statistically significant difference. Results: Most of the harvested spheroid cells were positive for nestin and 88.4% were positive forCD133. The CD133+ U87 cells were cultured into tube like structure loaded on the top of Matrigel and the quantity of tubes was decreased under the treatment of ATRA. In addition, the expressions of VEGF, VEGFR-2 and CD133 were significantly reduced under the treatment of ATRA, particularly in the higher concentration groups (20 and 40 μmol, P < 0.01). Conclusions: ATRA may inhibit the establishment of VM differing from stem cells in glioma, and these effects may attribute to the effects of ATRA’s promotion of the differentiation of stem cells and/or down regulation of the expressions of proangiogenic factors VEGF and its receptor VEGFR-2. Thus, the results of the present study indicated a novel idea for the treatment of GBM and enriched the anti-glioma mechanisms of ARTA.
Cite this paper: Tang, R. , Liang, C. , Shangguan, J. and Guo, S. (2017) The Effects of All-Trans Retinoic Acid on Vasculogenic Mimicry Formation Ability in CD133+ Glioma Stem Cells and Its Mechanisms. Journal of Biosciences and Medicines, 5, 42-54. doi: 10.4236/jbm.2017.54005.

[1]   Le Rhun, E., Rhun, E.L., Taillibert, S. and Chamberlain, M.C. (2015) The Future of High-Grade Glioma: Where We Are and Where Are We Going. Surgical Neurology International, 6, S9-S44.

[2]   Clarke, J., Butowski, N. and Chang, S. (2010) Recent Advances in Therapy for Glioblastoma. Archives of Neurology, 67, 279-283.

[3]   Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C. and Jouvet, A. (2007) The 2007 WHO Classification of Tumors of the Central Nervous System. Acta Neuropathologica, 114, 97-109.

[4]   Bai, R.Y., Staedtke, V. and Riggins, G.J. (2011) Molecular Targeting of Glioblastoma: Drug Discovery and Therapies. Trends in Molecular Medicine, 17, 301-312.

[5]   Vauleon, E., Avril, T., Collet, B., Mosser, J. and Quillien, V. (2010) Overview of Cellular Immunotherapy for Patients with Glioblastoma. Clinical and Developmental Immunology, 2010, Article ID: 689171.

[6]   Mohyeldin, A. and Chiocca, E.A. (2012) Gene and Viral Therapy for Glioblastoma: A Review of Clinical Trials and Future Directions. The Cancer Journal, 18, 82-88.

[7]   Wilson, T.A., Karajannis, M.A. and Harter, D.H. (2014) Glioblastoma Multiforme: State of the Art and Future Therapeutics. Surgical Neurology International, 5, 64.

[8]   Folkman, J. (1971) Tumor Angiogenesis: Therapeutic Implications. The New England Journal of Medicine, 285, 1182-1186.

[9]   Hardee, M.E. and Zagzag, D. (2012) Mechanisms of Glioma-Associated Neovascularization. American Journal of Pathology, 181, 1126-1141.

[10]   Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., et al. (1999) Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry. American Journal of Pathology, 155, 739-752.

[11]   Wang, J., Wakeman, T.P., Lathia, J.D., et al. (2010) Notch Promotes Radio Resistance of Glioma Stem Cells. Stem Cells, 28, 17-28.

[12]   Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., et al. (2012) A Restricted Cell Population Propagates Glioblastoma Growth after Chemotherapy. Nature, 488, 522-526.

[13]   Lai, C.Y., Schwartz, B.E. and Hsu, M.Y. (2012) CD133+ Melanoma Subpopulations Contribute to Perivascular Niche Morphogenesis and Tumorigenicity through Vasculogenic Mimicry. Cancer Research, 72, 5111-5118.

[14]   El Hallani, S., Boisselier, B., Sanson, M., et al. (2010) A New Alternative Mechanism in Glioblastoma Vascularization: Tubular Vasculogenic Mimicry. Brain, 133, 973-982.

[15]   Seftor, R.E., Hess, A.R., Hendrix, M.J., et al. (2012) Tumor Cell Vasculogenic Mimicry: From Controversy to Therapeutic Promise. American Journal of Pathology, 181,1115-1125.

[16]   Niu, C.S., Li, M.W., Ni, Y.F., et al. (2010) Effect of All-Trans Retinoic Acid on the Proliferation and Differentiation of Brain Tumor Stem Cells. Journal of Experimental & Clinical Cancer Research, 29, 113.

[17]   Campos, B., Wan, F., Farhadi, M., et al. (2010) Differentiation Therapy Exerts Antitumor Effects on Stem-Like Glioma Cells. Clinical Cancer Research, 16, 2715-2728.

[18]   Thaker, N.G. and Pollack, I.F. (2009) Molecularly Targeted Therapies for Malignant Glioma: Rationale for Combinatorial Strategies. Expert Review of Neurotherapeutics, 9, 1815.

[19]   Baowei, J., Qianxue, C., Baohui, L., Liquan, W., Daofeng, T., Zhentao, G. and Wei, Y. (2013) Glioma Stem Cell-Targeted Dendritic Cells as a Tumor Vaccine against Malignant Glioma. Yonsei Medical Journal, 54, 92-100.

[20]   Francescone, R.A. III, Faibish, M. and Shao, R. (2011) A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells. Journal of Visualized Experiments, No. 55, e3040.

[21]   David, L.S., Daniel, L. and Tyler, E.M. (2014) Brain Tumor Stem Cells: Molecular Characteristics and Their Impact on Therapy. Molecular Aspects of Medicine, 39, 82-101.

[22]   Misra, R.M., Bajaj, M.S. and Kale, V.P. (2012) Vasculogenic Mimicry of HT1080 Tumor Cells in Vivo: Critical Role of HIF-1 Alpha-Neuropilin-1 Axis. PLoS ONE, 7, e50153.

[23]   Sharma, N., Seftor, R.E., Seftor, E.A., et al. (2002) Prostatic Tumor Cell Plasticity Involves Cooperative Interactions of Distinct Phenotypic Subpopulations: Role in Vasculogenic Mimicry. Prostate, 50, 189-201.

[24]   Zhang, D., Sun, B., Chi, J., et al. (2014) Twist 1 Expression Induced by Sunitinib Accelerates Tumor Cell Vasculogenic Mimicry by Increasing the Population of CD133+ Cells in Triple-Negative Breast Cancer. Molecular Cancer, 13, 207.

[25]   Fujimoto, A., Onodera, H., Mori, A., et al. (2006) Tumour Plasticity and Extravascular Circulation in ECV304 Human Bladder Carcinoma Cells. Anticancer Research, 26, 59-69.

[26]   Su, M., Wei, W., Xu, X., et al. (2011) Role of hCG in Vasculogenic Mimicry in OVCAR-3 Ovarian Cancer Cell Line. International Journal of Gynecological Cancer, 21, 1366-1374.

[27]   Liu, W.B., Xu, G.L., Jia, W.D., et al. (2011) Prognostic Significance and Mechanisms of Patterned Matrix Vasculogenic Mimicry in Hepatocellular Carcinoma. Medical Oncology, 28, 228-238.

[28]   Li, M., Gu, Y., Zhang, Z., et al. (2010) Vasculogenic Mimicry: A New Prognostic Sign of Gastric Adenocarcinoma. Pathology and Oncology Research, 16, 259-266.

[29]   Kirschmann, D.A., Seftor, E.A., Hardy, K.M., Seftor, R.E.B. and Hendrix, M.J.C. (2012) Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications. Clinical Cancer Research, 18, 2726-2732.

[30]   Valyi-Nagy, K., Kormos, B., Ali, M., Shukla, D. and Valyi-Nagy, T. (2012) Stem Cell Marker CD271 Is Expressed by Vasculogenic Mimicry-Forming Uveal Melanoma Cells in Three-Dimensional Cultures. Molecular Vision, 18, 588-592.

[31]   Scully, S., Francescone, R., Faibish, M., et al. (2012) Trans-Differentiation of Glioblastoma Stem-Like Cells into Mural Cells Drives Vasculogenic Mimicry in Glioblastomas. Journal of Neuroscience, 32, 12950-12960.

[32]   Asou, N. (2007) All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. Internal Medicine, 46, 91-93.

[33]   Le Doze, F., Debruyne, D., Albessard, F., Barre, L. and Defer, G.L. (2000) Pharmacokinetics of All-Trans Retinoic Acid, 13-Cis Retinoic Acid, and Fenretinide in Plasma and Brain of Rat. Drug Metabolism & Disposition, 28, 2058-2088.

[34]   Karmakar, S., Banik, N.L. and Ray, S.K. (2008) Combination of All-Trans Retinoic Acid and Paclitaxel-Induced Differentiation and Apoptosis in Human Glioblastoma U87MG Xenografts in Nude Mice. Cancer, 112, 596-607.

[35]   Moro, M., Bertolini, G., Pastorino, U., Roz, L. and Sozzi, G. (2015) Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer. Journal of Thoracic Oncology, 10, 1027-1036.

[36]   Zhang, M.L., Tao, Y., Zhou, W.Q., et al. (2014) All-Trans Retinoic Acid Induces Cell-Cycle Arrest in Human Cutaneous Squamous Carcinoma Cells by Inhibiting the Mitogen-Activated Protein Kinase-Activated Protein 1 Pathway. Clinical and Experimental Dermatology, 39, 354-360.

[37]   Gumireddy, K., Sutton, L.N., Phillips, P.C. and Reddy, C.D. (2003) All-Trans-Retinoic Acid-Induced Apoptosis in Human Medulloblastoma: Activation of Caspase- 3/Poly(ADP-Ribose) Polymerase 1 Pathway. Clinical Cancer Research, 8, 4052-4059.

[38]   Chen, P.H., Shih, C.M., Chang, W.C., et al. (2014) MicroRNA-302b-Inhibited E2F3 Transcription Factor Is Related to All Trans Retinoic Acid-Induced Glioma Cell Apoptosis. Journal of Neurochemistry, 131, 731-742.

[39]   Ling, G., Liu, Y., Ke, Y., et al. (2015) All-Trans Retinoic Acid Impairs the Vasculogenic Mimicry Formation Ability of U87 Stem-Like Cells through Promoting Differentiation. Molecular Medicine Reports, 12, 165-172.

[40]   Witkiewicz, H., Oh, P. and Schnitzer, J.E. II (2013) Capsular Vaso-Mimicry Formed by Transgenic Mammary Tumor Spheroids Implanted Ectopically into Mouse Dorsal Skin Fold: Implications for Cellular Mechanisms of Metastasis. Version 2. F1000 Research, 2, 9.

[41]   Haigh, J.J. (2008) Role of VEGF in Organogenesis. Organogenesis, 4, 247-256.

[42]   Pitzer, M.R., Sortwell, C.E., Daley, B.F., et al. (2003) Angiogenic and Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF165): Studies of Grafted and Cultured embryonic Ventral Mesencephalic Cells. Experimental Neurology, 182, 435-445.

[43]   Shibuya, M. (2011) Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis. Genes Cancer, 2, 1097-1105.

[44]   Yao, X., Ping, Y., Bian, X., et al. (2013) Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Plays a Key Role in Vasculogenic Mimicry Formation, Neovascularization and Tumor Initiation by Glioma Stem-Like Cells. PLoS ONE, 8, e57188.

[45]   Francescone, R., Scully, S., Bentley, B., Yan, W., Taylor, S.L., Oh, D., Moral, L. and Shao, R. (2012) Glioblastoma-Derived Tumor Cells Induce Vasculogenic Mimicry through Flk-1 Protein Activation. The Journal of Biological Chemistry, 287, 24821-24831.

[46]   Nagy, J.A. and Dvorak, H.F. (2012) Heterogeneity of the Tumor Vasculature: The Need for New Tumor Blood Vessel Type-Specific Targets. Clinical and Experimental Metastasis, 29, 657-662.

[47]   Sitohy, B., Nagy, J.A., Jaminet, S.C. and Dvorak, H.F. (2011) Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy. Cancer Research, 71, 7021-7028.